RxDoctor Payments Data

Shivani Sood, MD

Gastroenterology · Norwich, CTNPI 1356500532

Payments from drug & device makers

$7,772in general payments, 2019–2025

Across 398 payments — averaging $19.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$948
  • Takeda Pharmaceuticals U.S.A., Inc.$785
  • Phathom Pharmaceuticals, Inc.$495
  • Johnson & Johnson$402
  • Pfizer$338
  • plus $2K from 30 others

What the payments were for

  • Consulting fees$180%
  • Speaking & faculty fees$4005%
  • Food & beverage$7,35495%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,772 in reported general payments places this provider in the 70th percentile of 326 gastroenterology providers in Connecticut.

See all gastroenterology providers in Connecticut

Medicare billing

Part B allowed, 2024
$106,848
Medicare patients
269
Services billed
1,843

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LinzessLinaclotide111$112,162
Mesalamine34$26,599
Dexlansoprazole DrDexlansoprazole79$25,274
TrulancePlecanatide27$24,900
Lubiprostone32$13,609
SutabSod Sulf/Pot Chloride/Mag Sulf47$7,682
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates124$7,577
Omeprazole391$6,769
Famotidine265$5,365
Ursodiol36$3,372
Pantoprazole Sodium225$3,185
Colestipol Hcl36$2,876
Esomeprazole Magnesium75$2,165
Dicyclomine Hcl86$1,948
PlenvuPeg3350/Sod Sul/Nacl/Kcl/Asb/C13$1,881

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess$2,354$112,162111 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCTrulance, Plenvu$948$26,78140 claims
Braintree Laboratories, Inc.Sutab$30$7,68247 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 326 gastroenterology providers in Connecticut.

Other gastroenterology in Norwich

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →